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Background: Many patients wish to stay at home during the terminal stage of cancer. However, there is concern
that medical care provided at home may negatively affect survival. This study therefore explored whether the
survival duration differed between cancer patients who received inpatient care and those who received home care.
Methods: We retrospectively investigated the place of care/death and survival duration of 190 cancer patients after
their referral to a palliative care consultation team in a Japanese general hospital between 2007 and 2012. The
patients were classified into a hospital care group consisting of those who received palliative care in the hospital
until death, and a home care group including patients who received palliative care at home from doctors in
collaboration with the palliative care consultation team. Details of the place of care, survival duration, and patient
characteristics (primary site, gender, age, history of chemotherapy, and performance status) were obtained from
electronic medical records, and analyzed after propensity score matching in the place of care.
Results: Median survival adjusted for propensity score was significantly longer in the home care group (67.0 days,
n = 69) than in the hospital care group (33.0 days, n = 69; P = 0.0013). Cox’s proportional hazard analysis revealed
that the place of care was a significant factor for survival following adjustment for covariates including performance
status.
Conclusions: This study suggests that the general concern that home care shortens the survival duration of
patients is not based on evidence. A cohort study including more known prognostic factors is necessary to confirm
the results.
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For cancer patients, dying in a preferred place is one of
the most important determinants of quality of life (QOL)
[1-4]. Multiple population-based surveys have indicated
that approximately half of Japanese people would desire
home care during terminal stage cancer [4,5], and a na-
tionwide bereaved family survey revealed that among all
patients dying of cancer, around 31% wanted to die at
home [1,6-8]. However, the actual figure of cancer patient
home deaths during the last decade in Japan was less than* Correspondence: tanabe@po2.nsknet.or.jp
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unless otherwise stated.10% [1,7,9]. Thus, the wishes of many Japanese cancer
patients do not appear to be met.
The major difference between hospital care and home-
based palliative care is the involvement of palliative care
specialists. Training for these specialists has recently
progressed and is offered mainly by the hospital. How-
ever, doctors in the home care are less exposed to these
training programs so often have little experience in pallia-
tive care, yet have to make important decisions including
the best methods for total pain relief, total or peripheral
parenteral nutrition, and the permission or prohibition of
oral feeding and hydration.
Empirical studies from Western countries have con-
firmed that when patients die in hospitals or intensive
care units, their QOL is often lower than that of patientsral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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atric disease development in bereaved families [2]. By
contrast, the shorter admission time to acute hospitals
during terminal stage cancer and the greater use of hos-
pice services at home may improve the patients QOL,
thus minimizing family mental stress [2].
The Japanese healthcare scheme has not established a
general practitioner system like that seen in Europe, and
patients have free access to all medical services covered
by universal national insurance [1,10]. A typical cancer
patient would therefore consult a cancer hospital, uni-
versity hospital, or large hospital directly, even when a
clinic is present nearby. Many Japanese people also be-
lieve that hospitals provide a higher quality of care than
clinics; for example, parenteral hydration is a minimum
requirement of hospitals even in patients whose death is
imminent [11]. Patients and their families have often
expressed concerns regarding the quality of home care,
and many believe that it results in a potentially shorter
survival during the terminal stage of cancer compared
with hospital care [12].
This study aimed to explore whether the survival
duration differed between terminally ill cancer patients
who received inpatient care and those who received
home care.
Methods
This retrospective study was based on propensity score
matching in the place of care of consecutive cancer pa-
tients referred to a palliative care team in a Japanese
270-bed designated cancer hospital (Saiseikai Takaoka
Hospital, Toyama, Japan). This study was approved by
the Institutional Review Board of Saiseikai Takaoka Hos-
pital. All subjects were adults, and provided their in-
formed consent for study participation.
Subjects
Subjects included 190 cancer patients who were consecu-
tively referred to a palliative care team between October
2007 and September 2012. We continuously followed the
patients from the start of palliative care team intervention
until their death or until the end of December 2012,
whichever was sooner.
Patients were classified into two groups based on the
place of care: (1) the hospital care group (patients who
received inpatient hospital care from their referral to the
palliative care team until their deaths, without discharge
to home), and (2) the home care group (patients who re-
ceived palliative home care for at least 1 day from home
doctors in collaboration with palliative care teams).
Interventions
In the hospital care group, the primary responsible phy-
sicians were attending hospital physicians other thanpalliative care specialties such as oncologists, surgeons,
and physicians certified in medical subspecialties. The
hospital palliative care consultation team provided regu-
lar daily monitoring, and was available 7 days a week
and 24 hours a day on demand.
In the home care group, the primary responsible phy-
sicians were home physicians in the community. The
hospital palliative care consultation team provided regular
weekly monitoring, and was available 7 days a week and
24 hours a day on demand. Additionally, information
was shared through one pre-discharge multidisciplinary
conference and via structured data sheets (information-
sharing instruments) [13]. Visiting physicians, nurses,
pharmacists, medical social workers, and other medical
staff completed the data sheets with comments for pa-
tients and relatives at each visit.
In both groups, palliative care was provided by a multi-
disciplinary care team, including physicians, nurses, phar-
macists, medical social workers, dietitians, and physical
therapists. The major differences between the groups were
therefore the primary physician and frequency of regular
palliative care consultation.Measurements
We retrospectively investigated the place of care and
duration of survival after referral of the patient to the
palliative care team using data from electronic medical
records. Additionally, as covariates, we investigated the
primary site, gender, age, history of chemotherapy from
1 month before referral to the time of death, and the
Eastern Cooperative Oncology Group (ECOG) perform-
ance status at the time of referral [14]. Palliative care
physicians had prospectively recorded patients’ perform-
ance statuses at the time of referral to a palliative care
team as routine practice. We counted the number of
completed records (as an alternative indicator of the
number of medical staff visits) to estimate the intensity
of home care only when relatives allowed us to use the
structured data sheets after the patient’s death. The pallia-
tive care team intervention duration matched the patient
survival time after intervention because we continuously
followed the patients until their deaths.Propensity score model
The propensity score was estimated using a logistic re-
gression model adjusted for primary site, gender, age,
history of chemotherapy, and ECOG performance status.
These variables were previously shown to be prognostic-
ally significant [15]. The matching algorithm on the pro-
pensity score was nearest neighbor matching with a
±0.04 caliper and without replacement. We used the
standardized difference to measure the variable balance,
whereby a standardized difference above 0.1 represented











46/48 55/41 0.25 0.17
Age (yr, mean ± SD) 72.7 ± 13.9 69.3 ± 10.9 0.06 0.28
Primary site (n) 0.45
Lung 12 19 0.19




Large intestine 16 9 0.23
Breast 2 4 0.12
Others 8 11 0.10
Performance status (n) 0.20
0 0 6 0.37
1 13 23 0.26
2 34 23 0.27
3 39 32 0.17
4 8 12 0.13
Use anti-cancer agents
(n, used/unused)a
3/91 3/93 1.00 0.004
aThis is about whether patients used anti-cancer agents or not from 1 month
before referral to Palliative Care Team to death.
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were calculated using the following formulae:









Xt : the mean of the home care group, St: the standard
deviation of the home care group,
Xc: the mean of the hospital care group, Sc: the standard
deviation of the hospital care group
<In the case of binary data>
d ¼ P^ t−P^c
 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
P^ t 1−P^ tð ÞþP^ c 1−P^ cð Þ
2
q
P^ t : the probability in the home care group, P^ c : the
probability in the hospital care group
Statistical analyses
The survival duration of patients in both groups was
compared using the log-rank test. Survival was defined
as the time from first referral to the palliative care team
until death. To adjust for factors that might have influ-
enced prognosis, we conducted a multivariate analysis
using the Cox proportional hazard model, in which pa-
tient background or propensity score were included as
covariates. Univariate comparisons were performed
using the Student’s t-test, Mann–Whitney U-test, or chi-
square test, as appropriate. The significance level was
established as 0.05. All statistical analyses were con-
ducted using IBM SPSS® Statistics version 22 software
(IBM Japan, Ltd. Tokyo, Japan.).
Results
A total of 94 patients were included in the home care
group and 96 in the hospital care group; four and one
patient from each respective group were still alive during
the observation periods. The median follow-up time by
the palliative care team was 57.0 days (range, 35–113
days) in the home care group and 33.5 days (range, 16–
67 days) in the hospital care group. After propensity
score matching, we analyzed 69 patients in both groups.
Characteristics of all patients and propensity-matched
patients are summarized in Tables 1 and 2, respectively.
No significant differences were observed between the
background factors of all patients, and no meaningful
imbalance was observed following propensity score
matching.
A total of 44/94 and 17/69 structured data sheets were
available for all home care patients and the matched co-
hort, respectively, and the average number of recordscompleted during home care (mean ± SD) was 41.3 ± 35.8
in all patients and 34.1 ± 25.0 in matched patients.
The log-rank test showed that matched patient survival
time was significantly longer in the home care group
(home care group: median, 67.0 days, range, 35–115 days
vs. hospital care group: median, 33.0 days, range, 15–72
days, P = 0.0013; Figure 1). Cox’s proportional hazard ana-
lysis revealed that the place of care was a significant factor
in predicting patient survival in all models (Table 3).
Discussion
The most important finding of this study was that survival
in the home care group was significantly longer than in
the hospital care group after adjustment for other factors,
such as performance status.
Several studies have previously examined the relation-
ship between place of death and survival in terminally ill
cancer patients [2,16,17]. In general, patients receiving
home care have been shown to survive for longer than
those who received hospital care [17]. However, a recent
survey reported no significant difference in survival be-
tween the two categories of patients [2]. A systematic re-
view of palliative home care showed that the prognosis
of patients receiving palliative home care was more fa-
vorable in some studies, whereas no difference was ob-
served in others [18]. Moreover, several randomized
controlled trials compared survival between home and











35/34 36/33 0.87 0.03
Age (yr, mean ± SD) 70.7 ± 13.9 70.7 ± 10.8 0.99 0.002
Primary site (n) 1.00
Lung 11 13 0.08




Large intestine 9 8 0.04
Breast 2 2 0
Others 8 8 0
Performance status (n) 0.99
0 0 0 (incalculable)
1 12 12 0
2 22 20 0.06
3 27 28 0.03
4 8 9 0.04
Use anti-cancer agents
(n, used/unused)a
1/68 2/67 1.00 0.10
aThis is about whether patients used anti-cancer agents or not from 1 month
before referral to Palliative Care Team to death.
Figure 1 Kaplan–Meier curves for adjusted overall survival
duration of propensity-matched patients stratified according to
the settings of palliative care. The median overall survival times
were 33.0 and 67.0 days for patients in hospital and home
care, respectively.
Table 3 Cox proportional hazard analysis of home care
and mortality
Model Hazard ratio 95% CI P
All patients
Unadjusted 0.61 0.46 – 0.82 <0.001
Adjusted for age, gender,
and performance status
0.53 0.39 – 0.72 <0.001
Propensity-matched patients
Unadjusted 0.58 0.41 – 0.81 0.002
Adjusted for propensity score 0.57 0.41 – 0.80 0.001
CI: confidence interval.
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cant difference between care types.
This study adds to the current body of knowledge on
the potential relationship between survival and place of
care, and confirms that most patients receiving home
care had significantly favorable, or at least no worse, sur-
vival profiles than those receiving hospital care. The
strengths of this study include the investigation of sur-
vival time as a primary end-point, and the adjustment
for factors influencing prognosis (such as performance
status). This study is also the first about this topic in
Asian patients who typically prefer hospital rather than
home care because of the concern that the latter could
shorten their survival [11,12]. Our findings that the
home care group had a significantly longer survival than
the hospital care group could help to dispel unsubstanti-
ated concerns about the negative effects of home care
on patient survival.
One of the potential interpretations of longer patient
survival at home is that the home care group had better
health than the hospital group. Although we adjusted for
performance status, which is one of the strongest prog-
nostic factors, this study was retrospective and investi-
gated only a limited number of prognostic variables.
Dyspnea, cachexia-related symptoms, and other inde-
pendent prognostic factors were not measured, and it is
conceivable that we failed to demonstrate the potential
backgrounds of patients in the two different treatment
settings. Another interpretation is that staying at home
might itself minimize patient distress through increasing
QOL, resulting in an improved immune system [22],
which could lead to improved survival. Alternatively, the
patients who received home care may have had a better
understanding of their disease status through facilitating
patient comprehension of the disease trajectory, which
could have minimized potentially harmful medical inter-
ventions close to their death [22]. These interpretations
should be tested in a future prospective study.
This study has a number of limitations. First, we could
not adjust for prognostic factors other than performance
status, such as nutrition, dyspnea, and delirium. Future
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for proven prognostic factors using the Palliative Prog-
nostic Index [23] or Palliative Prognostic Score [24].
Until then, the survival difference between the two pa-
tient groups cannot be confirmed. Second, this was a
retrospective survey, so the details of the quality of pal-
liative care are unknown. The data include both patients
with advanced cancer at their initial visit and those
whose cancer progressed to an advanced state during
treatment. Therefore, we cannot precisely calculate the
time period from advanced cancer until death. Third,
this was a single institutional study with a relatively
small sample size, and generalizability may be limited
because of potential differences in the availability of
community and hospital health care resources. Fourth,
neither the timing of the discontinuation of anti-cancer
drug regimens nor all of the details of cancer interven-
tions were available [15,25,26]. The results of this study
are therefore preliminary, and require a confirmatory
observation study that includes factors that influence
prognosis such as clinical stage, anti-cancer treatment,
comorbidity, and socio-economic characteristics.
Conclusion
The survival of patients who received home care was sig-
nificantly better, or at least not worse, than that of patients
who received palliative care in a hospital. Although the re-
sults of this study are only preliminary, they nevertheless
provide important evidence for suggesting home care to
patients and their families. A cohort study involving other
prognostic factors would confirm this observation to con-
clude whether palliative home care improves prognosis.
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